BioNxt Solutions (BNXT.CN) Osake Kurssi

BioNxt Solutions, Inc. engages in the business of producing, extracting, and selling medical cannabis. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-08-06. The firm is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The firm has research and development operations in North America and Europe, with an operational focus in Germany. The firm is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.